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To study whether Epstein-Barr virus (EBV) load can be used to predict the occurrence of
acquired immunodeficiency syndrome–related non-Hodgkin lymphoma (AIDS-NHL), we de-
termined EBV load longitudinally for individuals infected with human immunodeficiency virus
type 1. EBV load in peripheral blood mononuclear cells (PBMC) was high and displayed
considerable fluctuations over time, indicating that absolute EBV load in PBMC is not pre-
dictive of the development of AIDS-NHL. EBV DNA was also detectable in serum at some
time points but at a lower level.
Epstein-Barr virus (EBV) is a widespread human gamma her-
pesvirus, which persists in a latent form in B lymphocytes as
episomes in the B cell nucleus that can range from 5 to 500
episomes per infected B cell [1]. The latently infected B cells are
controlled by specific cytotoxic T lymphocyte responses [2]. In
human immunodeficiency virus (HIV) type 1–infected indi-
viduals, reactivation of EBV infection can lead to uncontrolled
lymphoproliferation [3], resulting in AIDS-related non-Hodgkin
lymphoma (AIDS-NHL). The majority of these AIDS-NHLs
are EBV-positive diffuse large B cell lymphomas (DLCLs) [4].
EBV load is a possible predictor of the occurrence of lym-
phoproliferative disorders [5]. Cross-sectional studies that used
semiquantitative and quantitative polymerase chain reaction
(PCR) assays to measure EBV load in peripheral blood mono-
nuclear cells (PBMC) or whole blood have shown that EBV
load at diagnosis was much higher in transplant recipients and
AIDS-NHL patients ( to 1 and 1 EBV4 6 54 10 1.5 10 2 10
copies/106 PBMC, respectively) [6–9] than in healthy EBV-se-
ropositive individuals (!0.1 to 5 EBV copies/106 PBMC) [6, 10].
Several studies have shown that high EBV load in serum or
plasma correlates with the occurrence of posttransplantation
lymphoma [11, 12].
The aim of this study was to determine whether EBV load
can be used to predict the occurrence of AIDS-NHL in HIV-
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infected individuals at an early stage. Therefore, we performed
a longitudinal study, using a real-time quantitative PCR assay
to determine the number of EBV virus DNA in both PBMC
and serum for different groups of HIV-infected individuals.
Patients, Materials, and Methods
Study population. This study was performed on longitudinal
PBMC and serum samples obtained from 21 HIV-1–infected ho-
mosexual men included in the Amsterdam Cohort Studies on HIV/
AIDS [13]. We studied several time points during HIV-positive
follow-up, from a few years after seroconversion or study entry
through AIDS diagnosis or late in HIV infection. The individuals
were selected to represent 3 distinct groups of HIV-infected indi-
viduals. For 9 individuals, AIDS-related diffuse large cell NHL
(AIDS-NHL) was the first AIDS-defining event. Seven individuals
progressed to AIDS (according to the classification of the Centers
for Disease Control and Prevention [14]) without developing a lym-
phoma (“progressors”) but had duration of follow-up similar to
that of the AIDS-NHL group (median duration, 94 months).
Among the progressors, 5 developed an opportunistic infection,
and 2 developed Kaposi sarcoma. Five individuals remained long-
term asymptomatic (LTA) with CD4 T cell counts 1500 cells/mm3
over the course of 18 years of HIV-seropositive follow-up (median
duration, 141 months).
Lymphocyte isolation and DNA extraction. Cryopreserved
PBMC ( cells) were lysed by addition of L6 lysis buffer.61 10
Genomic DNA was extracted by precipitation with isopropanol,
washed twice with 70% ethanol, and dissolved in distilled water.
To isolate DNA from serum, the QIAamp blood kit (Qiagen) was
used according to the protocol supplied by the manufacturer.
Real-time quantitative PCR assay. DNA from PBMC52 10
or 40 mL of serum was amplified in duplicate, using PCR primers
selective for the EBV DNA genome that encodes the nonglyco-
sylated membrane protein BNRF1 p143. PCR amplification was
performed, as described elsewhere [15], in a 50-mL volume con-
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taining 2 TaqMan Universal Mastermix (PE Biosystems) with
45 mM of the EBV/p143 forward primer 5′-GGA-ACC-TGG-TCA-
TCC-TTT-GC-3′ and 2.5 mM of reverse primer 5′-ACG-TGC-
ATG-GAC-CGG-TTA-AT-3′ (Isogen Biosciences). In the PCR, 5
pmol of a fluorogenic probe was added (5′-CGC-AGG-CAC-TCG-
TAC-TGC-TCG-CT-3′; PE Biosystems), with a FAM reported
molecule at the 5′ end and a TAMRA quencher at the 3′ end, to
detect amplified DNA.
Amplification and detection were performed with an ABI Prism
7700 Sequence Detection System (PE Biosystems). A threshold
cycle (Ct) value was calculated by determination of the point at
which the fluorescence exceeded a threshold limit of 0.04. Each run
contained negative controls (no template or EBV-negative DNA),
a positive control (a known amount of EBV copies), and a standard
serial half-log dilution of plasmid DNA containing the PCR prod-
uct as an insert (range, – copies/mL). The standard2 81 10 1 10
curve was created automatically with the ABI Prism 7700 software,
by plotting of the Ct values against each standard of known
concentration.
The assay was shown to detect as few as 50 EBV copies/mL of
plasma (2 copies/reaction) and had a linear range as high as
copies/mL. The assay is very accurate, with a variability71 10
(both intra-assay and interassay) of !3%; only in the low copy
number range does variability reach 12%.
Statistical analysis. Spearman’s correlation test was used to
correlate EBV copies in PBMC with EBV copies in serum. The
Wilcoxon signed rank test was used to compare EBV load at early
and late time points for the different groups, using SPSS software
(version 7.5 for Windows).
Results
Longitudinal analysis of EBV load in PBMC of HIV-1–in-
fected individuals. To investigate the kinetics of EBV load
during HIV-1 infection, we determined EBV load in 9 AIDS-
NHL patients with DLCLs, 5 LTA individuals, and 7 pro-
gressors. Figure 1 shows the results for 6 representative AIDS-
NHL patients, 3 LTA individuals, and 3 progressors. Over time,
most AIDS-NHL patients displayed bursts in EBV load (fig-
ure 1A) that could reach levels of 1 copies/106 PBMC61 10
(figure 1A, patient NHL8199). However, in most of these AIDS-
NHL patients, EBV load did not reach levels 1 copies/42 10
106 PBMC (figure 1A, patients NHL0292, NHL0068, and
NHL0118). EBV load at the time that AIDS-NHL was diag-
nosed was – copies/106 PBMC (figure 1A).3 61.4 10 3.1 10
This absolute amount of EBV DNA was not related to CD4
T cell numbers or HIV RNA load at the time of diagnosis or
to HIV-positive follow-up (data not shown).
Although in the LTA group, EBV load could be undetectable
early in the course of HIV-1 infection (figure 1B, patient
LTA1160), bursts of EBV load also were observed that reached
levels of copies/106 PBMC (figure 1B). Similarly, bursts47 10
of EBV load were observed in the group of progressors (figure
1C ). EBV load peaks varied from to copies/4 51 10 1.6 10
106 PBMC but decreased again to baseline values in most LTA
individuals and progressors. Bursts of EBV load were not
caused by increases in the number of B cells in the blood (data
not shown).
We calculated the mean EBV load for each individual both
early (approximately the first 4 years of follow-up) and late
(approximately the last 4 years of follow-up) in infection. As
shown in figure 2, there was no difference in absolute EBV load
(mean) between AIDS-NHL and LTA individuals, either early
or late in infection ( and , respectively; Mann-Pp .44 Pp .7
Whitney U test). The mean EBV load for AIDS-NHL patients
and that for the group of progressors also did not differ
( early in infection and late in infection; Mann-Pp .41 Pp 1
Whitney U test). In addition, no difference was found among
the 3 groups when we compared the highest peaks in EBV load
observed for each individual during the entire follow-up period
(data not shown). Interestingly, whereas LTA individuals and
progressors had a stable EBV load or a significant decrease
( for the LTA group and for the progressorPp .35 Pp .018
group; Wilcoxon test), 7 of 9 AIDS-NHL patients had an in-
crease in EBV load during the course of HIV-1 infection
( ; Wilcoxon test). The change in EBV load for AIDS-Pp .05
NHL patients was significantly different from that for pro-
gressors ( ; Mann-Whitney U test).P ! .008
EBV load in PBMC versus EBV load in serum. We sub-
sequently compared the EBV load in PBMC with that in se-
rum for 7 AIDS-NHL patients, 3 LTA individuals, and 1 pro-
gressor from whom serum samples were available at the same
time points. Figure 1A and 1B shows the results for 4 AIDS-
NHL patients (patients NHL0068, NHL0118, NHL0308, and
NHL6006) and 2 LTA individuals (patients LTA0750 and
LTA0036). In most individuals at some time points EBV could
be detected in serum. Levels were much lower, however, than
levels in PBMC, and the kinetics often were different. One
AIDS-NHL patient had detectable levels of EBV in serum only
at the last time point studied (figure 1A, patient NHL0068).
Interestingly, a high peak in the serum load occurred when the
load in PBMC was decreasing after initiation of highly active
antiretroviral therapy (figure 1A, patient NHL0068) and fol-
lowing the initiation of successful chemotherapy after a diag-
nosis of lymphoma was made (figure 1A, patient NHL6006).
Overall, no correlation between EBV load in PBMC and
EBV load in serum was found (data not shown).
Discussion
In the present study, we investigated the kinetics of EBV load
in PBMC and serum in different groups of HIV-1–infected in-
dividuals, using a real-time quantitative PCR assay. We ob-
served bursts in the EBV load in PBMC in all subgroups of
HIV-infected patients that we studied and found that the ab-
solute EBV load is not predictive of whether AIDS-NHL will
develop. Furthermore, there is no clear correlation between
EBV load in PBMC and EBV load in serum.
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Figure 1. Epstein-Barr virus (EBV) load in peripheral blood mononuclear cells (PBMC; solid lines) and in serum (dashed lines) for 12 individuals
with human immunodeficiency virus infection, measured by a real-time quantitative polymerase chain reaction assay. Measurements were made
beginning a few years after seroconversion or on study entry and continued until (A) the diagnosis of AIDS-related non-Hodgkin lymphoma
(NHL), for those who developed lymphoma ( ); (B) late in infection, for long-term asymptomatic (LTA) individuals ( ); or (C) thenp 6 np 3
diagnosis of AIDS, for those who progressed to AIDS but did not develop a lymphoma (PROG; ). Black arrows indicate diagnosis of NHLnp 3
or AIDS-related opportunistic infection (AIDS-OI). White arrows indicate initiation of chemotherapy (CHOP) or highly active antiretroviral
therapy (HAART).
The EBV load found in HIV-1 infected individuals in the pres-
ent study was comparable with that reported elsewhere for pe-
diatric bone marrow transplant recipients with lymphoprolifer-
ative disorders [6–8, 16] and for patients with AIDS-NHL [9].
The latter study did show a relationship between high EBV load
and the development of a lymphoma, but no other groups of
HIV-infected individuals were investigated. Although EBV load
measurements seemed to be useful for predicting the development
of a lymphoma in transplant recipients, this did not appear to
be the case for HIV-infected individuals. Of course, the first study
group was more homogeneous; all patients received similar im-
munosuppressive treatment regimens (e.g., similar dosages) [6–8,
16], whereas, in the present study, the HIV-infected individuals
all had different virologic and immunologic status. Because, on
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Figure 2. Mean Epstein-Barr virus (EBV) load in peripheral blood
mononuclear cells (PBMC) both early (approximately the first 4 years
of follow-up) and late (approximately the last 4 years of follow-up) in
infection for 21 individuals with human immunodeficiency virus in-
fection, measured by a real-time quantitative polymerase chain reaction
assay. Data for long-term asymptomatic (LTA) individuals ( ) arenp 5
represented by dark gray dashed lines; for those who developed AIDS-
related non-Hodgkin lymphoma (AIDS-NHL; ), by solid lines;np 9
and for those who progressed to AIDS without developing a lymphoma
(PROG; ), by light gray dashed lines.np 7
the one hand, EBV load was high in all HIV-infected individuals,
and, on the other, some of the AIDS-NHL patients did not have
an EBV load 1 copies/106 PBMC, other factors must be42 10
involved in the development of NHL in HIV-infected individuals.
Although EBV load alone may not be predictive of AIDS-
NHL, the combination of measurements of EBV load and of
cellular immunity against EBV may provide more information
on the balance between virus and host and, thus, may have
predictive value. As shown in our previous study [17], the com-
bination of a low EBV load with collapsing cellular immunity
against EBV results in a higher risk of AIDS-NHL than does
the combination of a high EBV load with stable numbers of
EBV-specific CD8 T lymphocytes [17]. Similarly, the return of
EBV load from peak to baseline values in LTA individuals and
patients with AIDS who develop opportunistic infections sug-
gests that EBV control is occurring. Furthermore, when the
mean EBV load for early and for late follow-up was calculated,
the load remained stable in LTA individuals, whereas AIDS-
NHL patients show a significant increase in EBV load during
the course of HIV-1 infection.
We found that the kinetics of EBV load in PBMC differs
from that in serum. Overall, EBV load in serum was lower than
load in PBMC and was often undetectable. In only 1 of 9 AIDS-
NHL patients was EBV load in serum high at the time that
AIDS-NHL was diagnosed. In addition, an increase in EBV
load in serum was usually observed after a peak in EBV load
in PBMC. This may be due to elimination or apoptosis of EBV-
infected B cells, resulting in the release of free EBV DNA into
serum. When a lymphoma is present, the number of cell-free
EBV DNA copies can be high because of the frequently ob-
served spontaneous apoptosis of tumor cells or because of tu-
mor lysis resulting from chemotherapy.
In conclusion, among HIV-1 infected individuals, absolute
EBV load is high and is not predictive of the development of
AIDS-NHL, although an overall increase in EBV load seems
to parallel the occurrence of AIDS-NHL. This suggests that
the risk for AIDS-NHL is not solely determined by EBV load.
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